Fuente: PubMed "hive" Am J Transl Res. 2026 Mar 15;18(3):2114-2124. doi: 10.62347/VTMH9009. eCollection 2026.ABSTRACTOBJECTIVE: To compare standard dose maintenance treatment (SDMT) and extended interval dose reduction treatment (EIDRT) in controlling patients with chronic spontaneous urticaria (CSU) during disease control phase, mainly focusing on time to treatment discontinuation, relapse rate, and pharmacoeconomic outcomes.METHODS: This retrospective cohort study included 258 CSU patients treated with omalizumab (Xolair®) between May 2023 and April 2025. Patients were divided into SDMT (n=120) and EIDRT (n=138) groups according to their dose-reduction strategy received during disease control phase. Patients in the SDMT group continued to receive omalizumab at a dose of 300 mg every 4 weeks until complete disease control (Urticaria control test [UCT] score ≥ 16) was obtained, followed by treatment discontinuation. In the EIDRT group, the dosing interval was gradually extended to every 8 weeks during the control phase. Demographic characteristics, clinical data, Urticaria Activity Score over 7 days (UAS7), UCT, Chronic Urticaria Quality of Life Questionnaire (CU-QoL), Dermatology Life Quality Index (DLQI), relapse rate after discontinuation, and pharmacoeconomic indicators were collected and analyzed.RESULTS: The EIDRT group demonstrated a significantly longer time to treatment discontinuation (10.27 ± 1.23 mo vs 9.82 ± 1.18 mo, P=0.003) and a lower relapse rate within 6 months after discontinuation (11.59% vs 23.33%, P=0.012), compared to the SDMT group. The EIDRT group required fewer omalizumab administrations (8.21 ± 0.76 vs 9.82 ± 1.25 doses, P < 0.001) and outpatient visits (9.08 ± 1.37 vs 11.35 ± 1.42 visits, P < 0.001) than the control group, with superior pharmacoeconomic outcomes. Multivariate logistic regression analysis identified EIDRT as an independent protective factor for relapse (OR=0.373, 95% CI: 0.189-0.739), whereas higher disease duration (OR=1.063, 95% CI: 1.014-1.115) and concomitant angioedema (OR=2.399, 95% CI: 1.330-4.329) were independently associated with an increased risk of relapse.CONCLUSION: Compared to SDMT, EIDRT was associated with a longer time to treatment discontinuation, a lower post-discontinuation relapse rate, and improved pharmacoeconomic outcomes in patients with CSU during the control phase.PMID:42007138 | PMC:PMC13090939 | DOI:10.62347/VTMH9009